Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0313 • ACR Convergence 2022
Olokizumab Improves Patient Reported Outcomes in Moderate to Severely Active Rheumatoid Arthritis Patients Inadequately Controlled by Methotrexate (MTX-IR): Results from the Phase III Randomized Controlled Trial
Vibeke Strand¹, Evgeny Nasonov², Tatiana Lisitsyna², Alexander Lila², Sofia Kuzkina³, Mikhail Samsonov⁴ and Eugen Feist⁵, ¹Stanford University School of Medicine, Stanford, CA, ²V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ³R-Pharm, Moscow, Russia, ⁴R-Pharm JSC, Moscow, Russia, ⁵Helios Clinic Vogelsang-Gommern, cooperation partner of the Otto von Guericke University Magdeburg, Magdeburg, Germany
Background/Purpose: Olokizumab (OKZ) is an interleukin-6-inhibitor for treatment of Rheumatoid Arthritis (RA). In these analyses, we present patient reported outcomes (PROs) reported by MTX-IR patients…
Abstract Number: 0535 • ACR Convergence 2022
Increase Rates of Bacterial Infection in Patients with ‘Pre-RA’
Duncan Porter¹, Sahil Jain² and Fraser Morton³, ¹Gartnavel General Hospital, Bearsden, United Kingdom, ²Gartnavel General Hospital, Glasgow, Scotland, United Kingdom, ³University of Glasgow, Glasgow, Scotland, United Kingdom
Background/Purpose: In 'pre-RA' there is evidence of disordered immunity manifest by the presence of auto-antibodies, increased concentration of pro-inflammatory cytokines (e.g. TNF) and acute phase…
Abstract Number: 0593 • ACR Convergence 2022
A New Cytokine Interleukin 40 Is Elevated in the Serum of Patients with Early Rheumatoid Arthritis and Associates with Autoantibodies and Neutrophil Activation
Adéla Navrátilová¹, Viktor Bečvář¹, Hana Hulejová¹, Michal Tomcik², Heřman Mann², Olga Růžičková¹, Olga Šléglová³, Jakub Závada¹, Karel Pavelka⁴, Jiří Vencovský⁵, Ladislav Šenolt⁵ and Lucie Andrés Cerezo¹, ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³Institute of Rheumatology, Prague, ⁴Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha, Czech Republic, ⁵Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: IL-40 is a newly described cytokine related to malignant transformation and immune system function. In our previous study, we showed that IL-40 is elevated…
Abstract Number: 0610 • ACR Convergence 2022
Patient-derived Organoids Reveal Transcriptional Regulation of Synovial Lining Fibroblast Differentiation
Sonia Presti¹, Gerald FM Watts¹, Zhu Zhu¹, Kartik Bhamidipati¹, Junning Case¹, Yuhong Li¹, Teri Bowman¹, Suppawat Kongthong¹, ilya Korsunsky¹, Michael Brenner² and Kevin Wei³, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Synovial lining fibroblasts secrete factors into the joint cavity that promote joint lubrication1. In inflammatory arthritis, sublining fibroblasts undergo marked expansion while lining fibroblasts…
Abstract Number: 0627 • ACR Convergence 2022
Spatial Transcriptomic Analysis Reveals Vascular Zonation of Myofibroblasts in Rheumatoid Arthritis Synovium
Kartik Bhamidipati¹, Roopa Madhu¹, Sonia Presti¹, Youngmi Kim², Ye Cui², Fan Zhang³, Anna Jonsson¹, Aparna Nathan¹, Nghia Millard¹, Deepak Rao¹, Laura Donlin⁴, Jennifer Anolik⁵, Soumya Raychaudhuri¹, Michael Brenner⁶, Ilya Korsunsky¹ and Kevin Wei⁷, ¹Brigham and Women's Hospital, Boston, MA, ²Nanostring Technologies Inc., Seattle, WA, ³University of Colorado, Aurora, CO, ⁴Hospital for Special Surgery, New York, NY, ⁵University of Rochester Medical Center, Rochester, NY, ⁶Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Many rheumatoid arthritis (RA) patients do not achieve sustained remission despite multiple lines of therapy. Recent studies have linked the expansion of synovial fibroblasts…
Abstract Number: 0762 • ACR Convergence 2022
Rituximab-treated Rheumatic Patients: B-cell Levels Predict Sero-conversion After COVID-19 Boost or Re-vaccination in Initial Vaccine Non-responders
Christian Ammitzboell¹, marianne Kragh thomsen², Jakob Bøgn Andersen¹, Jens Magnus Berth Jensen³, marie-Louise From Hermansen¹, anders Dahl Johannsen¹, Mads Lamm Larsen¹, Clara Elbæl Mistegaard¹, Susan Mikkelsen³, Fruzsina Szabados³, Signe Risbøl Vils¹, Christian Erikstrup³, Ellen-Margrethe Hauge¹ and Anne Troldborg¹, ¹Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ²Department of Clinical Microbiology, Aarhus University Hospital, Aarhus, Denmark, ³Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Treatment with rituximab (RTX) has presented a challenge during the COVID-19 pandemic, as antibody response after primary vaccination are markedly reduced and often undetectable.The primary…
Abstract Number: 0883 • ACR Convergence 2022
Serum Cholesterol Loading Capacity on Macrophages Is Dependent on Oxidized Low-density Lipoprotein and Regulated by Seropositivity and C-reactive Protein in Patients with Rheumatoid Arthritis
George A Karpouzas¹, Bianca Papotti², Sarah Ormseth³, Marcella Palumbo², elizabeth Hernandez³, Maria Pia Adorni², Francesca Zimetti², Matthew Budoff⁴ and Nicoletta Ronda⁵, ¹Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ²University of Parma, Parma, Italy, ³The Lundquist Institute, Torrance, CA, ⁴Harbor-UCLA Medical Center and the Lundquist Institute, Torrance, CA, ⁵University of Parma, Parma
Background/Purpose: Excessive cholesterol accumulation in macrophages underlies foam cell formation, initiation and progression of atherosclerosis. Low-density lipoprotein (LDL) oxidation and unregulated uptake by macrophages are…
Abstract Number: 0899 • ACR Convergence 2022
Performance of the Foot Function Index Questionnaire in Patients with Rheumatoid Arthritis
Joan Manuel Dapeña, Lucia Alascio, Eliana Rebeca Serrano, Juan Manuel Bande, Maria Alejandra Medina, Diana Silvia Klajn, Jose Angel Caracciolo and Silvia Beatriz Papasidero, Hospital General de Agudos Dr. Enrique Tornu, Buenos Aires, Argentina
Background/Purpose: Multiple questionnaires and objective assessment tools have been developed to determine functional compromise in Rheumatoid Arthritis (RA). One of the most used tools to…
Abstract Number: 0915 • ACR Convergence 2022
Methotrexate Therapy Results in Disparate Methotrexate Polyglutamate Profiles in Peripheral Blood Mononuclear Cells Compared with Erythrocytes
Renske Hebing¹, Marry Lin², Sohaila Mahmoud³, Ittai B. Muller², Sandra Heil⁴, Pieter Griffioen⁴, Eduard A. Struys², Willem Lems⁵, Bart van den Bemt⁶, Michael Nurmohamed⁷, Gerrit Jansen⁸ and Robert De Jonge⁹, ¹Amsterdam Rheumatology and immunology Center, Amsterdam UMC – location Reade, Amsterdam, Netherlands, ²Department of Clinical Chemistry, Amsterdam University Medical Centers – location VUMC, Amsterdam, Netherlands, ³Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, Netherlands, ⁴Department of Clinical Chemistry, Erasmus MC, Rotterdam, Netherlands, ⁵Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁶Department of Pharmacy, Sint Maartenskliniek, Ubbergen, Netherlands, ⁷Amsterdam University Medical Center, Kortenhoef, Netherlands, ⁸Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers – location VUMC, Amsterdam, Netherlands, ⁹Department of Clinical Chemistry, Amsterdam University Medical Centers, Amsterdam, Netherlands
Background/Purpose: Analyses of methotrexate polyglutamates (MTX-PGs) in red blood cells (RBCs) has been employed as tool for personalized therapy approach for RA patients during MTX…
Abstract Number: 0931 • ACR Convergence 2022
Rituximab versus Leflunomide in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis Despite Methotrexate Treatment- an Open Label Randomized Controlled Trial
Rashmi Roongta¹, Geetabali Sircar¹, Parasar Ghosh², Dipendranath Ghosh¹ and Hiramanik Sit¹, ¹Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India, ²Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India
Background/Purpose: Active rheumatoid arthritis (RA) despite methotrexate (MTX) monotherapy is seen in about 40-50% of patients1. The current ACR guidelines recommend adding a biologic or…
Abstract Number: 1123 • ACR Convergence 2022
Excess of Rare Deleterious Variants Within JAK-STAT Pathway – Related Genes in Patients with Rheumatoid Arthritis Associated Interstitial Lung Disease
Pierre-Antoine Juge¹, Steven Gazal², Raphaël Borie³, Lidwine Wemeau⁴, Marie-Pierre Debray⁵, Sebastien Ottaviani⁶, Sylvain Marchand Adam⁷, Christophe Richez⁸, Hilario Nunes⁹, Pascal Richette¹⁰, Caroline Kannengiesser¹¹, Jérome Avouac¹², Jean Sibilia¹³, René-Marc Flipo¹⁴, Vincent Cottin¹⁵, Thierry Schaeverbeke¹⁶, Martin Soubrier¹⁷, Nathalie Saidenberg-Kermanac’h¹⁸, Dominique Valeyre¹⁹, Catherine Boileau¹¹, Bruno Crestani²⁰ and Philippe Dieude²¹, ¹Rheumatology department, Bichat Hospital, Paris, France, ²University of Southern California, Los Angeles, CA, ³Pulmonology department, Bichat Hospital, Paris, France, ⁴Pulmonology department, Lille University hospital, Lille, France, ⁵Radiology department, Hôpital Bichat, Paris, France, ⁶Hopital Bichat-Claude Bernard, Paris, France, ⁷Pulmonology department, Tours University Hospital, Tours, France, ⁸Université de Bordeaux, Bordeaux, France, ⁹Pulmonology department, Hopital Avicenne, Bobigny, France, ¹⁰Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France, ¹¹Genetic Department, Bichat hospital, Paris, France, ¹²Rheumatology Department, Cochin hospital, Paris, France, ¹³University Hospital of Strasbourg, Strasbourg, France, ¹⁴Hôpital Roger Salengro, Lille, France, ¹⁵Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, ¹⁶FHU ACRONIM, University Hospital of Bordeaux, University of Bordeaux, Bordeaux, France, ¹⁷Gabriel-Montpied Hospital, Clermont-Ferrand, France, ¹⁸Rheumatology Department, Avicenne Hospital, Bobigny, France, ¹⁹Pulmonology department, Avicenne Hospital, Bobigny, France, ²⁰Hopital Bichat, Paris University, Paris, France, ²¹Université Paris Cité, Paris, France
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of morbidity and mortality in patients with RA. To date, there are no specific treatments available…
Abstract Number: 1238 • ACR Convergence 2022
Can Thermal Imaging Help Clarify Joint Inflammation at Clinically Quiescent Metacarpophalangeal Joints in Patients with Rheumatoid Arthritis?
York Kiat Tan, Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore
Background/Purpose: Ultrasound (US) is superior to clinical examination and can be used for more accurate assessment of joint inflammation in rheumatoid arthritis (RA). However, it…
Abstract Number: 1351 • ACR Convergence 2022
Development, Implementation, and Usability Testing of a New Rheumatoid Arthritis Patient-Reported Outcomes EHR-based Dashboard: A Mixed-Method Study
Cammie Young¹, Anna Montgomery², Catherine Nasrallah³, Lindsay Jacobsohn⁴, Jennifer Barton⁵, Sara Murray⁴, Jinoos Yazdany⁶ and Gabriela Schmajuk⁷, ¹University of California San Francisco, San Francisco, CA, ²University of California, San Francisco, USA; San Francisco VA Medical Center, San Francisco, USA, San Francisco, CA, ³UCSF, San Francisco, ⁴University of California, San Francisco, San Francisco, CA, ⁵VA Portland Health Care System/OHSU, Portland, OR, ⁶UCSF, San Francisco, CA, ⁷UCSF / SFVA, San Francisco, CA
Background/Purpose: Shared decision making is a key component of a treat-to-target approach for the treatment of rheumatoid arthritis (RA). We created an EHR tool that…
Abstract Number: 1399 • ACR Convergence 2022
Inflammatory Arthritis Genetic Risk Factors to Predict Treatment Patterns in Rheumatoid Arthritis
Gregory McDermott¹, Jing Cui¹, Rachel Knevel², Kumar Dahal¹, Dana Weisenfeld¹, Priyam Das³, Elizabeth Karlson¹, Su-Chun Cheng⁴, Soumya Raychaudhuri¹, Tianxi Cai⁴ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Leiden University Medical Center, Leiden, Netherlands, ³Harvard Medical School, Boston, MA, ⁴Harvard TH Chan School of Public Health, Boston, MA
Background/Purpose: In a prior study, we described an alternative method for subphenotyping RA patients by the sequence of biologic DMARDs (bDMARDs) they receive over time.…
Abstract Number: 1415 • ACR Convergence 2022
Different Bioactive Lipid Profile Predicts Response to TNF or IL6 Inhibitors in Rheumatoid Arthritis: Result of the CorEvitas CERTAIN Comparative Effectiveness Study
Mona Alotaibi¹, Roxana Coras², Dimitrios Pappas³, Ted Mikuls⁴, Joel Kremer⁵, Geoffrey Thiele⁶, mohit jain¹ and Monica Guma⁷, ¹Department of Medicine, School of Medicine, University of California San Diego, San Diego, CA, ²University of California San Diego, San Diego, CA, ³CorEvitas, LLC, Waltham, MA, ⁴Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁵The Corrona Research Foundation, Delray Beach, FL, ⁶University of Nebraska Medical Center, Omaha, NE, ⁷UCSD, La Jolla, CA
Background/Purpose: Circulating bioactive lipids can provide information about the pathogenesis of specific diseases and potentially help predict therapeutic response. Choosing the right biological therapy earlier…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].